• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素 6 通过降低人肝癌细胞中蛋白酪氨酸磷酸酶受体型 O 的表达促进单核细胞和巨噬细胞中 PD-L1 的表达。

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.

机构信息

Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

Department of Immunology, Nanjing Medical University, Nanjing, China.

出版信息

J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000285.

DOI:10.1136/jitc-2019-000285
PMID:32581055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7319788/
Abstract

BACKGROUND

We have previously discovered a relationship between the low expression of protein tyrosine phosphatase, receptor type O (PTPRO) in tumor-infiltrating T cells and immunosuppression. The aim of the present study was to investigate the relationship between decreased PTPRO and increased programmed death ligand 1 (PD-L1) in both the peripheral monocytes and tumor-infiltrating macrophages of human hepatocellular carcinoma (HCC).

METHODS

The expression and correlation of all the indices were explored in monocytes and tumor-infiltrating macrophages within both human and mice HCC. The mechanic regulations were studied by using both in vitro and in vivo studies.

RESULTS

We found a significant decrease in PTPRO in HCC peripheral monocytes that was associated with increased PD-L1 expression in peripheral monocytes and tumor-associated macrophages (TAMs) in HCC. Monocyte PD-L1 and PTPRO therefore could serve as valuable prognostic indicators for post-surgery patients with HCC and were associated with increased T-cell exhaustion (Tim3+T cells). A depletion of PTPRO promoted PD-L1 secretion in both monocytes and macrophages through the JAK2/STAT1 and JAK2/STAT3/c-MYC pathways. Increased IL-6 expression was associated with activation of JAK2/STAT3/c-MYC and with decreased PTPRO expression through the STAT3/c-MYC/miR-25-3 p axis. Monocytes and TAMs showed significantly increased miR-25-3 p expression, which could target the 3' untranslated region of PTPRO. The miR-25-3 p expression positively correlated with serum IL-6 levels, but inversely correlated with PTPRO in HCC monocytes. IL-6/STAT3/c-MYC activation enhanced in vitro miR-25-3 p transcription and decreased PTPRO, while further promoting PD-L1 secretion. Adoptive cell transfer of c-MYC/miR-25-3 p-modified monocytes promoted tumor growth by downregulating PTPRO and causing a PD-L1-induced immunosuppression in an orthotopic tumor transplantation model.

CONCLUSIONS

Increased serum IL-6 downregulated PTPRO expression in HCC monocytes and macrophages by activating STAT3/c-MYC/miR-25-3 p and by further enhancing PD-L1 expression through JAK2/STAT1 and JAK2/STAT3/c-MYC signaling.

摘要

背景

我们之前发现肿瘤浸润 T 细胞中蛋白酪氨酸磷酸酶受体 O(PTPRO)表达降低与免疫抑制有关。本研究旨在探讨人肝癌(HCC)外周单核细胞和肿瘤浸润巨噬细胞中 PTPRO 减少与程序性死亡配体 1(PD-L1)增加之间的关系。

方法

在人和小鼠 HCC 中探索外周单核细胞和肿瘤浸润巨噬细胞中所有指标的表达和相关性。通过体外和体内研究研究了机械调节规律。

结果

我们发现 HCC 外周单核细胞中 PTPRO 表达显著降低,与 HCC 外周单核细胞和肿瘤相关巨噬细胞(TAMs)中 PD-L1 表达增加相关。单核细胞 PD-L1 和 PTPRO 因此可以作为 HCC 术后患者有价值的预后指标,并与 T 细胞耗竭(Tim3+T 细胞)增加相关。PTPRO 耗竭通过 JAK2/STAT1 和 JAK2/STAT3/c-MYC 途径促进单核细胞和巨噬细胞中 PD-L1 的分泌。IL-6 表达增加与 JAK2/STAT3/c-MYC 的激活以及通过 STAT3/c-MYC/miR-25-3p 轴降低 PTPRO 表达有关。单核细胞和 TAMs 显示出明显增加的 miR-25-3p 表达,可靶向 PTPRO 的 3'非翻译区。miR-25-3p 表达与 HCC 单核细胞中的血清 IL-6 水平呈正相关,与 PTPRO 呈负相关。IL-6/STAT3/c-MYC 激活增强了体外 miR-25-3p 转录并降低了 PTPRO,同时进一步促进了 PD-L1 的分泌。c-MYC/miR-25-3p 修饰的单核细胞的过继细胞转移通过下调 PTPRO 并在原位肿瘤移植模型中引起 PD-L1 诱导的免疫抑制,促进肿瘤生长。

结论

通过激活 STAT3/c-MYC/miR-25-3p,以及通过 JAK2/STAT1 和 JAK2/STAT3/c-MYC 信号进一步增强 PD-L1 表达,HCC 单核细胞和巨噬细胞中的血清 IL-6 下调 PTPRO 表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/7817a205b6f3/jitc-2019-000285f07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/b4d62b7766b7/jitc-2019-000285f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/fed0184ed130/jitc-2019-000285f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/e9df919fff86/jitc-2019-000285f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/8cddbd6a8b12/jitc-2019-000285f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/7ced54b444f2/jitc-2019-000285f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/37cf53178fb2/jitc-2019-000285f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/7817a205b6f3/jitc-2019-000285f07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/b4d62b7766b7/jitc-2019-000285f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/fed0184ed130/jitc-2019-000285f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/e9df919fff86/jitc-2019-000285f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/8cddbd6a8b12/jitc-2019-000285f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/7ced54b444f2/jitc-2019-000285f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/37cf53178fb2/jitc-2019-000285f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda8/7319788/7817a205b6f3/jitc-2019-000285f07.jpg

相似文献

1
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.白细胞介素 6 通过降低人肝癌细胞中蛋白酪氨酸磷酸酶受体型 O 的表达促进单核细胞和巨噬细胞中 PD-L1 的表达。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000285.
2
Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.肿瘤周围单核细胞的糖酵解激活通过 PFKFB3-PD-L1 轴促进人肝癌中的免疫特权。
J Hepatol. 2019 Aug;71(2):333-343. doi: 10.1016/j.jhep.2019.04.007. Epub 2019 May 7.
3
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.骨桥蛋白诱导集落刺激因子 1 信号破坏肿瘤相关巨噬细胞的迁移,使肝细胞癌对抗 PD-L1 阻断敏感。
Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22.
4
Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.阻断低氧诱导的表达在髓系细胞上的触发受体 1 阳性肿瘤相关巨噬细胞可逆转肝癌中的免疫抑制和抗程序性细胞死亡配体 1 耐药性。
Hepatology. 2019 Jul;70(1):198-214. doi: 10.1002/hep.30593. Epub 2019 Apr 12.
5
TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.TGF-β1 诱导的 SOX18 升高通过转录上调 PD-L1 和 CXCL12 促进肝细胞癌的进展和转移。
Gastroenterology. 2024 Jul;167(2):264-280. doi: 10.1053/j.gastro.2024.02.025. Epub 2024 Feb 27.
6
Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.肿瘤细胞释放的自噬体(TRAPs)通过诱导 PD-L1 表达增加的 M2 样巨噬细胞促进免疫抑制。
J Immunother Cancer. 2018 Dec 18;6(1):151. doi: 10.1186/s40425-018-0452-5.
7
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.SIRT7 缺失通过 MEF2D 调控程序性细胞死亡配体 1 增加肝癌细胞中检查点抑制剂的疗效。
Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
8
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.口腔鳞状细胞癌通过诱导肿瘤相关巨噬细胞上的PD-L1表达来抑制抗肿瘤免疫。
Immunobiology. 2017 Apr;222(4):651-657. doi: 10.1016/j.imbio.2016.12.002. Epub 2016 Dec 14.
9
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.肿瘤相关巨噬细胞中程序性死亡配体 1 蛋白的优先表达及其在肝癌免疫治疗中的潜在作用。
Int J Mol Sci. 2021 Apr 29;22(9):4710. doi: 10.3390/ijms22094710.
10
Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.靶向 YB-1/PD-L1 轴增强化疗和抗肿瘤免疫。
Cancer Immunol Res. 2019 Jul;7(7):1135-1147. doi: 10.1158/2326-6066.CIR-18-0648. Epub 2019 May 21.

引用本文的文献

1
Paracetamol Induces Apoptosis, Reduces Colony Formation, and Increases PTPRO Gene Expression in Human Embryonic Kidney HEK 293 Cells.对乙酰氨基酚诱导人胚肾HEK 293细胞凋亡、减少集落形成并增加PTPRO基因表达。
J Biochem Mol Toxicol. 2025 Aug;39(8):e70366. doi: 10.1002/jbt.70366.
2
Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (Nano) and PD-1 antibody.通过一氧化氮供体纳米颗粒(Nano)与PD-1抗体的协同作用增强癌症免疫疗法。
Sci Technol Adv Mater. 2025 Jul 29;26(1):2538430. doi: 10.1080/14686996.2025.2538430. eCollection 2025.
3
Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy.

本文引用的文献

1
Precursor exhausted T cells: key to successful immunotherapy?前体细胞耗竭 T 细胞:免疫治疗的关键?
Nat Rev Immunol. 2020 Feb;20(2):128-136. doi: 10.1038/s41577-019-0223-7. Epub 2019 Oct 7.
2
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.肿瘤微环境在 PD-L1/PD-1 介导的肿瘤免疫逃逸中的作用。
Mol Cancer. 2019 Jan 15;18(1):10. doi: 10.1186/s12943-018-0928-4.
3
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
癌症免疫治疗中的程序性死亡-1配体1结构域组织、信号基序及相互作用分子
Cancers (Basel). 2025 May 12;17(10):1635. doi: 10.3390/cancers17101635.
4
Intersection of Cardio-Oncology: An Overview of Radiation-Induced Heart Disease in the Context of Tumors.心脏肿瘤学交叉领域:肿瘤背景下放射性心脏病概述
J Am Heart Assoc. 2025 May 20;14(10):e040937. doi: 10.1161/JAHA.124.040937. Epub 2025 May 13.
5
PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma.程序性死亡受体1(PD-1)阻断可减轻手术诱导的免疫抑制,并提高光动力疗法治疗胸膜间皮瘤的疗效。
Cancer Res Commun. 2025 May 1;5(5):841-856. doi: 10.1158/2767-9764.CRC-24-0571.
6
Immunohistochemical expression of PD-L1 in colorectal carcinoma among black patients and the clinicopathological correlates: a cross-sectional study.黑人患者结直肠癌中PD-L1的免疫组化表达及其临床病理相关性:一项横断面研究。
BMC Gastroenterol. 2025 Apr 20;25(1):277. doi: 10.1186/s12876-025-03862-7.
7
Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers.TMPRSS2表达与癌症中肿瘤免疫原性及对免疫检查点抑制剂反应的关联
J Transl Med. 2025 Mar 7;23(1):294. doi: 10.1186/s12967-025-06177-z.
8
Novel insights into the impact of liver inflammatory responses on primary liver cancer development.关于肝脏炎症反应对原发性肝癌发展影响的新见解。
Liver Res. 2023 Feb 3;7(1):26-34. doi: 10.1016/j.livres.2023.01.001. eCollection 2023 Mar.
9
Variations in salivary microbiome and metabolites are associated with immunotherapy efficacy in patients with advanced NSCLC.唾液微生物群和代谢产物的变化与晚期非小细胞肺癌患者的免疫治疗疗效相关。
mSystems. 2025 Mar 18;10(3):e0111524. doi: 10.1128/msystems.01115-24. Epub 2025 Feb 10.
10
IL-6 and PD-1 antibody blockade combination therapy regulate inflammation and T lymphocyte apoptosis in murine model of sepsis.白细胞介素-6与程序性死亡蛋白-1抗体阻断联合疗法可调节脓毒症小鼠模型中的炎症反应和T淋巴细胞凋亡。
BMC Immunol. 2025 Jan 14;26(1):3. doi: 10.1186/s12865-024-00679-z.
帕博利珠单抗治疗晚期、转移性食管腺癌或鳞状细胞癌的大量预处理患者的疗效和安全性:Ⅱ期 KEYNOTE-180 研究。
JAMA Oncol. 2019 Apr 1;5(4):546-550. doi: 10.1001/jamaoncol.2018.5441.
4
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.癌症免疫治疗的范式转变:从增强到正常化。
Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035.
5
IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.白细胞介素-6通过信号转导和转录激活因子3、信号转导和转录激活因子6以及碱性亮氨酸拉链转录因子BATF的协同作用增强白细胞介素-4诱导的原代人巨噬细胞极化。
Oncoimmunology. 2018 Jul 30;7(10):e1494110. doi: 10.1080/2162402X.2018.1494110. eCollection 2018.
6
CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma.CCL15 招募抑制性单核细胞促进肝癌中的免疫逃逸和疾病进展。
Hepatology. 2019 Jan;69(1):143-159. doi: 10.1002/hep.30134. Epub 2018 Dec 31.
7
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.联合阻断 IL6 和 PD-1/PD-L1 信号通路可消除肿瘤微环境中它们免疫抑制作用的相互调节。
Cancer Res. 2018 Sep 1;78(17):5011-5022. doi: 10.1158/0008-5472.CAN-18-0118. Epub 2018 Jul 2.
8
Safety of combining radiotherapy with immune-checkpoint inhibition.放疗与免疫检查点抑制联合应用的安全性。
Nat Rev Clin Oncol. 2018 Aug;15(8):477-494. doi: 10.1038/s41571-018-0046-7.
9
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.程序性死亡配体 1 在癌症中的遗传、转录和翻译后调控:生物学和临床相关性。
Oncogene. 2018 Aug;37(34):4639-4661. doi: 10.1038/s41388-018-0303-3. Epub 2018 May 16.
10
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境(TIME)以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.